{"abstract":"The National Heart, Lung, and Blood Institute (\"NHLBI\"), an institute of the National Institutes of Health; an agency within the Department of Health and Human Services, is contemplating the grant of an exclusive patent license to commercialize the invention(s) embodied in the intellectual property estate stated in the Summary Information section of this notice to Precision IBD, Inc., located in San Diego, California, and incorporated under the laws of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/05/07/2018-09654.html","cfr_references":[],"citation":"83 FR 20081","comment_url":null,"comments_close_on":"2018-05-22","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development on or before May 22, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-09654","effective_on":null,"end_page":20082,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/05/07/2018-09654.xml","html_url":"https://www.federalregister.gov/documents/2018/05/07/2018-09654/prospective-grant-of-exclusive-patent-license-antibodies-against-tl1a-a-tnf-family-cytokine-for-the","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-09654?publication_date=2018-05-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-05-07/2018-09654/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":286,"last_updated":"2026-09-22 22:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-05-07/pdf/2018-09654.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-09654.pdf?1525437937","publication_date":"2018-05-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/05/07/2018-09654.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T19:54:58Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":20081,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Crohn's Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis","toc_doc":"Antibodies Against TL1A, a TNF-Family Cytokine, for Treatment and Diagnosis of Crohn's Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis","toc_subject":"Exclusive Patent Licenses; Proposed Approvals:","topics":[],"type":"Notice","volume":83}